Premium
Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: impact of combination assays of immune function and CYP3A5 genotype
Author(s) -
Mizuno Shugo,
Hamada Takashi,
Nakatani Kaname,
Kishiwada Masashi,
Usui Masanobu,
Sakurai Hiroyuki,
Tabata Masami,
Sakamoto Yuko,
Nishioka Junji,
Muraki Yuichi,
Okuda Masahiro,
Nobori Tsutomu,
Isaji Shuji
Publication year - 2011
Publication title -
journal of hepato‐biliary‐pancreatic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 1868-6974
DOI - 10.1007/s00534-010-0335-8
Subject(s) - tacrolimus , immune system , medicine , genotype , cyp3a5 , allele , gastroenterology , transplantation , immunology , liver transplantation , pharmacology , biology , genetics , gene
Background The immune response after living donor liver transplantation (LDLT) was evaluated, with specific attention focused on the inter‐relationship among clinical conditions, pharmacokinetics of tacrolimus, and cytochrome P450 3A5 (CYP3A5) genotypes. Methods Forty 40 adult patients who underwent LDLT in the period 2002–2009 were enrolled in the study. Peripheral blood was collected from these patients between June 2009 and December 2009 and analyzed for CD4+ adenosine triphosphate (ATP) activity (ImmuKnow assay), tacrolimus concentration, and CYP3A5 genotype. Based on the results of the ImmuKnow assay (i.e., strength of immune response), each patient was categorized into one of the three established zones of immune response: Group A (low response, n = 13), Group B (moderate response, n = 24), and Group C (strong response, n = 3). Results There was no correlation between the concentration of tacrolimus and ATP levels in the blood. The patients in Group A required much higher tacrolimus doses to maintain the blood concentration, as evidenced by the tacrolimus concentration/dose (C/D) ratios in Group A being significantly lower than those in Group B. Almost half of the patients in Group A suffered from infectious complications. The C/D ratios were significantly lower in the six patients with the CYP3A5*1 allele than in the 14 patients with the CYP3A5*3 allele; one‐half of the patients with the CYP3A5*1 allele belonged to Group A. Conclusions Our results demonstrate that the immunKnow assay of immune function is an excellent tool for monitoring immune response, especially in the patients with CYP3A5*1 allele (expressors).